NOTICE:

In 2010, Optherion completed two separate business transactions, one related to its diagnostics business and one related to its therapeutics business.

With respect to its diagnostics business, in February, 2010, Optherion completed an exclusive worldwide licensing agreement with Sequenom, Inc.. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Please see News Room at Optherion.com for Sequenom’s press release.

With respect to its therapeutics business, also in 2010, Optherion completed a business transaction with another company. Both the company name and the transaction economics are confidential.

As a result of these two transactions, Optherion, itself, is no longer actively developing any diagnostics or therapeutics. Given this, the Optherion.com website has not been updated since year-end, 2010 albeit the nature of Optherion’s diagnostic and therapeutic endeavors are accurately represented in the website for the time period prior to the transactions.

Kindest regards,

Colin J. Foster
President & CEO
Optherion, Inc.

Diagnostics

Optherion is developing a genetic and biomarker platform that will identify individuals at risk of developing AMD, and predict the disease progression and treatment outcome in diagnosed patients.  Enhanced awareness of risk will provide actionable information upon which medical professionals can intervene more aggressively with recommended lifestyle changes, and facilitate advanced planning for available therapies.  Optherion has acquired an extensive portfolio of intellectual properties comprised of genetic and protein biomarkers associated with AMD.  Through an extensive R&D program and an active business development/licensing effort, Optherion aims to offer a best-in-class diagnostic platform for AMD.